CellSource Co., Ltd. (4880.T)
JPY 844.0
(-1.97%)
JPY 844.0
(-1.97%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 677.73 Million JPY | -16.76% |
| 2022 | 814.15 Million JPY | 26.22% |
| 2021 | 645 Million JPY | 108.31% |
| 2020 | 309.63 Million JPY | 32.02% |
| 2019 | 234.53 Million JPY | -20.7% |
| 2018 | 295.76 Million JPY | 147.35% |
| 2017 | 119.57 Million JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 694.31 Million JPY | -10.93% |
| 2024 Q2 | 779.5 Million JPY | -7.93% |
| 2024 Q1 | 846.63 Million JPY | 24.92% |
| 2023 Q4 | 677.73 Million JPY | 27.78% |
| 2023 FY | 677.73 Million JPY | -16.76% |
| 2023 Q3 | 530.38 Million JPY | -13.16% |
| 2023 Q2 | 610.73 Million JPY | 48.62% |
| 2023 Q1 | 410.95 Million JPY | -49.52% |
| 2022 Q2 | 497.26 Million JPY | 56.4% |
| 2022 Q1 | 317.94 Million JPY | -50.71% |
| 2022 Q4 | 814.15 Million JPY | 70.66% |
| 2022 FY | 814.15 Million JPY | 26.22% |
| 2022 Q3 | 477.07 Million JPY | -4.06% |
| 2021 Q1 | 288.07 Million JPY | -6.96% |
| 2021 Q2 | 424.51 Million JPY | 47.36% |
| 2021 Q3 | 509.9 Million JPY | 20.11% |
| 2021 Q4 | 645 Million JPY | 26.5% |
| 2021 FY | 645 Million JPY | 108.31% |
| 2020 FY | 309.63 Million JPY | 32.02% |
| 2020 Q1 | 238.4 Million JPY | 1.65% |
| 2020 Q4 | 309.63 Million JPY | 46.66% |
| 2020 Q3 | 211.12 Million JPY | -13.96% |
| 2020 Q2 | 245.38 Million JPY | 2.93% |
| 2019 Q3 | 182.3 Million JPY | 0.0% |
| 2019 Q4 | 234.53 Million JPY | 28.65% |
| 2019 FY | 234.53 Million JPY | -20.7% |
| 2018 FY | 295.76 Million JPY | 147.35% |
| 2017 FY | 119.57 Million JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 3.24 Billion JPY | 79.127% |
| PRISM BioLab Co.,LTD | 63.41 Million JPY | -968.804% |
| GNI Group Ltd. | 26.34 Billion JPY | 97.427% |
| Linical Co., Ltd. | 10.3 Billion JPY | 93.423% |
| Trans Genic Inc. | 3.81 Billion JPY | 82.223% |
| MEDINET Co., Ltd. | 590.2 Million JPY | -14.831% |
| Soiken Holdings Inc. | 697.02 Million JPY | 2.767% |
| Cytori Cell Research Institute, Inc. | 3.02 Billion JPY | 77.564% |
| AnGes, Inc. | 2.78 Billion JPY | 75.703% |
| OncoTherapy Science, Inc. | 513.6 Million JPY | -31.957% |
| Nxera Pharma Co., Ltd. | 90.38 Billion JPY | 99.25% |
| Immuno-Biological Laboratories Co., Ltd. | 353.27 Million JPY | -91.847% |
| NanoCarrier Co., Ltd. | 1.64 Billion JPY | 58.922% |
| Carna Biosciences, Inc. | 472.35 Million JPY | -43.481% |
| CanBas Co., Ltd. | 91.98 Million JPY | -636.769% |
| D. Western Therapeutics Institute, Inc. | 1.09 Billion JPY | 38.027% |
| RaQualia Pharma Inc. | 809.83 Million JPY | 16.311% |
| Chiome Bioscience Inc. | 593.73 Million JPY | -14.149% |
| Kidswell Bio Corporation | 4.25 Billion JPY | 84.068% |
| PeptiDream Inc. | 29.11 Billion JPY | 97.672% |
| Oncolys BioPharma Inc. | 566.5 Million JPY | -19.636% |
| Ribomic Inc. | 155.8 Million JPY | -334.981% |
| SanBio Company Limited | 2.25 Billion JPY | 69.944% |
| Healios K.K. | 11.28 Billion JPY | 93.995% |
| BrightPath Biotherapeutics Co., Ltd. | 251.26 Million JPY | -169.726% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 369 Million JPY | -83.669% |
| Delta-Fly Pharma, Inc. | 241.49 Million JPY | -180.641% |
| StemRIM | 187 Million JPY | -262.427% |
| FunPep Company Limited | 189.32 Million JPY | -257.978% |
| Kringle Pharma, Inc. | 596.95 Million JPY | -13.533% |
| Stella Pharma Corporation | 1.44 Billion JPY | 53.052% |
| TMS Co., Ltd. | 97.68 Million JPY | -593.772% |
| Noile-Immune Biotech Inc. | 91.49 Million JPY | -640.747% |
| Cuorips Inc. | 200.96 Million JPY | -237.249% |
| K Pharma,Inc. | 209.13 Million JPY | -224.069% |
| Takara Bio Inc. | 11.42 Billion JPY | 94.065% |
| ReproCELL Incorporated | 741.03 Million JPY | 8.541% |
| PhoenixBio Co., Ltd. | 917.71 Million JPY | 26.149% |
| StemCell Institute Inc. | 3.85 Billion JPY | 82.399% |
| Japan Tissue Engineering Co., Ltd. | 908.43 Million JPY | 25.395% |
| CellSeed Inc. | 301.04 Million JPY | -125.127% |